AFP Expression is a predictive biomarker for use of ramucirumab in patients.
Of the therapies with AFP Expression as a predictive biomarker, 1 is FDA-approved and 1 has NCCN guidelines in at least one clinical setting.
Hepatocellular carcinoma has the most therapies targeted against AFP Expression or its related pathways .
Hepatocellular Carcinoma -
Sample must match one or more of the following:
|Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Second Line of Therapy (FDA, NCCN)|
|Note: Ramucirumab has been approved as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.|
AFP Expression serves as an inclusion eligibility criterion in 6 clinical trials, of which 6 are open and 0 are closed. Of the trials that contain AFP Expression as an inclusion criterion, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).
Trials with AFP Expression in the inclusion eligibility criteria most commonly target hepatocellular carcinoma, adenocarcinoma of the gastroesophageal junction, and gastric adenocarcinoma .
C-tcr055, et140202, anti-pd-l1 monoclonal antibody, autologous genetically modified afpc332t cells, and capecitabine are the most frequent therapies in trials with AFP Expression as an inclusion criteria .
Significance of AFP Expression in Diseases
Hepatocellular Carcinoma +
AFP Expression is an inclusion criterion in 5 clinical trials for hepatocellular carcinoma, of which 5 are open and 0 are closed. Of the trials that contain AFP Expression and hepatocellular carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) .
Ramucirumab has evidence of efficacy in patients with AFP Expression in hepatocellular carcinoma .
Adenocarcinoma Of The Gastroesophageal Junction +
AFP Expression is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains AFP Expression and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) .
Gastric Adenocarcinoma +
AFP Expression is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AFP Expression and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.